Mega Ovarian Cancer Screening Trial Shows Modest Reduction in Mortality
Abstract
One of the largest ever randomized trials has concluded that ovarian cancer screening may reduce ovarian cancer mortality by an estimated 20% after up to 14 years (Jacobs IJ et al. Lancet. doi:10.1016/S0140-6736(15)01224-6 [published online December 17, 2015]). Ovarian cancer has had a poor prognosis for 3 decades; currently, less than 30% of patients are diagnosed at an early, potentially curable, stage. A recent trial investigates the benefits of ovarian cancer screening. Steve...